FoxO1 as the critical target of puerarin to inhibit osteoclastogenesis and bone resorption.
Yanling FengXulei TangPublished in: The Journal of pharmacy and pharmacology (2024)
Puerarin improved the OPG/RANKL ratio, upregulated the protein expression and transcriptional activity of FoxO1, and suppressed the differentiation of RAW264.7 cells into osteoclasts. FoxO1 is a pivotal target of puerarin to confer anti-osteoporosis effects.